智通财经APP获悉，信达生物(01801)涨超14%，截至发稿，涨14.21%，报44.6港元，成交额11.09亿港元。
消息面上，信达生物公布2024年业绩，收入约94.22亿元，同比增长51.8%；毛利约79.12亿元，同比增长56.1%；年内亏损9463.1万元，同比收窄90.8%。非国际财务报告准则(Non-IFRS)下，公司扭亏为盈，实现利润近3.32亿元人民币，去年同期亏损5.15亿元；EBITDA取得4.1亿元，去年同期亏损6亿元。公司表示，接下来锚定2027年实现200亿产品收入、2030年实现5个管线进入全球III期临床研究的战略性目标。
另值得一提的是，信达生物今早宣布，将在2025年美国癌症研究协会（AACR）年会上公布多项最新临床前数据，包括公司旗下一系列双抗、多抗及抗体偶联药物（ADC）肿瘤管线。本届 AACR年会将于当地时间2025年4月25日-30日在美国芝加哥举办。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.